Conference
The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis
Abstract
OBJECTIVE: The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab-treated patients achieved complete withdrawal of oral glucocorticoids (OGCs). The objectives of this post hoc analyses are to further elucidate the efficacy of benralizumab and mepolizumab in facilitating reductions in OGCs through investigating …
Authors
Nair PK; Hellmich B; Bourdin A; Jayne DRW; Roufosse F; Khalidi N; Sjö LB; Fan Y; McCrae C; Necander S
Publisher
Wiley
Publication Date
September 22, 2025
DOI
10.1002/art.43398
Conference proceedings
Arthritis & Rheumatology
ISSN
2326-5191